Merck announced ACIP voted to recommend Enflosnia (clesrovimab-cfor) as a treatment option for RSV in infants younger than 8 months of age who are born during or entering their first RSV season.

Under the deal, cash-paying patients can access a month's supply of Wegovy through the Danish drugmaker's Novocare pharmacy ...

Alternatives to weekly injections of weight-loss drugs may be on the way. A monthly dose of a new drug called MariTide helped ...

Regeneron Pharmaceuticals, Inc. faces challenges with Eylea sales but sees growth from Dupixent and obesity drugs. Click for ...

While some compounding pharmacies have stopped making alternatives to Wegovy and Zepbound since shortages were declared over, ...

US drugmakers are betting they can turn upfront payments of as little as $80 million into multibillion-dollar treatments.

Image source: Getty Images. Going up against a giant. Regeneron signed a deal with China-based Hansoh Pharma for HS-20094, an investigational, late-stage anti-obesity asset.

The drug is currently undergoing a phase 2b in diabetes and a phase 3 in obesity in China. 4. Astellas aspires to strike CLDN18.2 gold again with ADC licensing deal worth up to $1.34B ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

REGN inks a $2B-plus obesity drug deal with Hansoh, ... Regeneron Pharmaceuticals, Inc. REGN is looking to make inroads in the lucrative obesity market.

REGN inks a $2B-plus obesity drug deal with Hansoh, ... Regeneron Pharmaceuticals, Inc. REGN is looking to make inroads in the lucrative obesity market.

Regeneron also expanded its portfolio of weight-loss medicines, announcing on Monday a deal for most worldwide rights to a drug developed by Hansoh Pharmaceuticals Group that's currently in late-stage ...